[Form 4] Organon & Co. Insider Trading Activity

Rhea-AI Filing Summary

Organon & Co. (OGN): Insider equity update. On 11/07/2025, the Head of R&D & CMO reported the conversion of restricted stock units into 6,446 shares of common stock at $0 per share (code M). To cover taxes, 2,307 shares were withheld at $6.71 per share (code F). Following these transactions, direct beneficial ownership is 28,916.355 shares.

The filing notes an RSU grant vesting in three installments: 6,446 shares on November 7, 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026. After the reported activity, 6,447 RSUs remain outstanding, expiring on November 7, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arjona Ferreira Juan Camilo

(Last) (First) (Middle)

C/O ORGANON &CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NJ 07302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		M		6,446	A	$0	31,223.355	D
Common Stock	11/07/2025		F		2,307	D	$6.71	28,916.355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/07/2025		M			6,446	11/07/2024(2)	11/07/2026	Common Stock	6,446	$0	6,447	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

2. These restricted stock units vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026.

Remarks:

	/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OGN report on 11/07/2025?

The Head of R&D & CMO converted restricted stock units into 6,446 shares of common stock (code M) and had 2,307 shares withheld for taxes (code F).

How many OGN shares does the reporting person own after the transactions?

Direct beneficial ownership is 28,916.355 shares following the reported transactions.

What price was used for the tax withholding on OGN shares?

Shares were withheld at $6.71 per share to cover taxes.

What is the RSU vesting schedule disclosed for OGN?

RSUs vest in three installments: 6,446 on Nov 7, 2024; 6,446 on Nov 7, 2025; and 6,447 on Nov 7, 2026.

How many OGN RSUs remain after the reported transaction?

6,447 RSUs remain outstanding, expiring on November 7, 2026.

Who filed the OGN Form 4 and what is their role?

The reporting person is an officer of Organon & Co., serving as Head of R&D & CMO.